Breast Cancer Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023
The global breast cancer treatment market is expected to increase with significant CAGR due to increasing prevalence and incidence of breast cancer cases. Rising awareness about breast cancer stages and treatment, government initiatives, and improving healthcare infrastructure are driving the breast cancer treatment market. Moreover, the rise in the healthcare expenditure, increase in the diabetic and obese population, increased spending on medicines, increasing consumption of alcohol and tobacco, and rising female population age of 65 years and above are expected to fuel the breast cancer treatment market over the forecast period. Furthermore, increase in the investments in research and developments, development of targeted drug delivery systems, and advancement in cancer biology & pharmacology might boost the breast cancer treatment market. However, drug development challenges in developing countries, long-term side effects of drugs, high costs associated with drug development, stringent regulatory guidelines, and patent expiry of drugs might hamper the growth of breast cancer treatment market in the forecast years.
Breast cancer is the disease occurs when uncontrolled growth of malignant cells in the breast tissue that is most commonly occurs in female than men. Treatment of breast cancer depends on various factors such as the type of breast cancer, the size of a tumour, stage of breast cancer and the grade of cancer cells. The breast cancer can be treated by various therapies such as radiation therapy, chemotherapy, hormone therapy, targeted therapy and bone-directed therapy. The common signs and symptoms associated with breast cancer include change in the breast shape, forming of lumps in the breast, dimpling of skin, and red scaly patches on the skin. In severe conditions, bone pain, swelling of lymph nodes, problems in respiration, and yellow skin may appear. The breast cancer commonly occurs due to drinking alcohol, being female, obesity, ionizing radiation, family history and older age among others. The breast cancer is diagnosed by taking a biopsy of lump. After the diagnosis, further tests are carried to determine the cancer stage and suitable treatment for the disease.
The breast cancer treatment market is segmented based on the treatment mechanism, treatment type, and distribution channel
Based on treatment mechanism, the breast cancer treatment market has been segmented into the following:
Local
Adjuvant
Neoadjuvant
Systemic
Based on drug class, the breast cancer treatment market has been segmented into the following:
Chemotherapy
Anthracyclines
Antimetabolites
Epothilones
Taxanes
Alkylating agents
Hormonal therapy
Aromatase inhibitors
Selective Oestrogen-receptor modulators
Based on the distribution channel, the breast cancer treatment market has been segmented into the following:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global breast cancer treatment market is in developing stage, owing to increase in the prevalence rate of breast cancer disease. According to World Health Organization, about 2000 new cases in men and approximately 200,000 new breast cancer cases in women are diagnosed. Most of the pharmaceutical companies in breast cancer treatment market are focus on research and development activities, strategic collaborations, acquisitions & mergers, and product launches for the development of their revenue in the breast cancer treatment market. For instance, in March 2017, Novartis has received FDA approval for its drug kisqali (ribociclib, LEE011) used as first-line treatment for the HR+/HER2 metastatic breast cancer along with aromatase inhibitor. Similarly, In September 2013, The U.S. Food and Drug Administration granted the accelerated approval for Perjeta (pertuzumab) used in the treatment of early stage breast cancer treatment before surgery. The innovation of some innovative therapy with better success rate is expected to offer a good opportunity for breast cancer treatment market.
Geographically, the breast cancer treatment market has been segmented into following regions Viz. Europe, Latin America, Middle East and Africa, Asia-Pacific, and North America. North America dominates the breast cancer treatment market mainly attributed to high prevalence of breast cancer disease, increase in female aging population, and favourable government initiatives for the treatment. Furthermore, increase in the healthcare infrastructure, favourable reimbursement policies, and high incorporation of targeted therapies also propel the breast cancer treatment market growth in North America region. Europe holds a major share in breast cancer treatment market owing to rise in the prevalence and incidence of breast cancer cases (According to World Cancer Research Fund International, nearly 1.7 million new breast cancer cases were diagnosed in 2012. In the UK itself, 53,696 new cases were diagnosed in 2013).
Some of the players in breast cancer treatment market are AstraZeneca (U.K.), GlaxoSmithKline plc (U.K.), Eli Lilly and Company (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Sanofi (France), Pfizer, Inc (U.S.). Sun Pharmaceutical Industries Ltd (India), Actavis, Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Bayer AG (Germany), Teva Pharmaceutical Industries. Ltd. (Israel), Puma Biotechnology, Inc. (U.S.), and OncoGenex Pharmaceuticals Inc. (U.S.) to name a few.
In July 2017, U.S. FDA Approved the Puma Biotechnology’s Nerlynx (Neratinib) for the treatment of HER2-positive breast cancer in early stage
In July 2017, AstraZeneca received the approval from European Commission (EC) for Faslodex (fulvestrant) for the breast cancer treatment
Breast cancer is the disease occurs when uncontrolled growth of malignant cells in the breast tissue that is most commonly occurs in female than men. Treatment of breast cancer depends on various factors such as the type of breast cancer, the size of a tumour, stage of breast cancer and the grade of cancer cells. The breast cancer can be treated by various therapies such as radiation therapy, chemotherapy, hormone therapy, targeted therapy and bone-directed therapy. The common signs and symptoms associated with breast cancer include change in the breast shape, forming of lumps in the breast, dimpling of skin, and red scaly patches on the skin. In severe conditions, bone pain, swelling of lymph nodes, problems in respiration, and yellow skin may appear. The breast cancer commonly occurs due to drinking alcohol, being female, obesity, ionizing radiation, family history and older age among others. The breast cancer is diagnosed by taking a biopsy of lump. After the diagnosis, further tests are carried to determine the cancer stage and suitable treatment for the disease.
The breast cancer treatment market is segmented based on the treatment mechanism, treatment type, and distribution channel
Based on treatment mechanism, the breast cancer treatment market has been segmented into the following:
Local
Adjuvant
Neoadjuvant
Systemic
Based on drug class, the breast cancer treatment market has been segmented into the following:
Chemotherapy
Anthracyclines
Antimetabolites
Epothilones
Taxanes
Alkylating agents
Hormonal therapy
Aromatase inhibitors
Selective Oestrogen-receptor modulators
Based on the distribution channel, the breast cancer treatment market has been segmented into the following:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global breast cancer treatment market is in developing stage, owing to increase in the prevalence rate of breast cancer disease. According to World Health Organization, about 2000 new cases in men and approximately 200,000 new breast cancer cases in women are diagnosed. Most of the pharmaceutical companies in breast cancer treatment market are focus on research and development activities, strategic collaborations, acquisitions & mergers, and product launches for the development of their revenue in the breast cancer treatment market. For instance, in March 2017, Novartis has received FDA approval for its drug kisqali (ribociclib, LEE011) used as first-line treatment for the HR+/HER2 metastatic breast cancer along with aromatase inhibitor. Similarly, In September 2013, The U.S. Food and Drug Administration granted the accelerated approval for Perjeta (pertuzumab) used in the treatment of early stage breast cancer treatment before surgery. The innovation of some innovative therapy with better success rate is expected to offer a good opportunity for breast cancer treatment market.
Geographically, the breast cancer treatment market has been segmented into following regions Viz. Europe, Latin America, Middle East and Africa, Asia-Pacific, and North America. North America dominates the breast cancer treatment market mainly attributed to high prevalence of breast cancer disease, increase in female aging population, and favourable government initiatives for the treatment. Furthermore, increase in the healthcare infrastructure, favourable reimbursement policies, and high incorporation of targeted therapies also propel the breast cancer treatment market growth in North America region. Europe holds a major share in breast cancer treatment market owing to rise in the prevalence and incidence of breast cancer cases (According to World Cancer Research Fund International, nearly 1.7 million new breast cancer cases were diagnosed in 2012. In the UK itself, 53,696 new cases were diagnosed in 2013).
Some of the players in breast cancer treatment market are AstraZeneca (U.K.), GlaxoSmithKline plc (U.K.), Eli Lilly and Company (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Sanofi (France), Pfizer, Inc (U.S.). Sun Pharmaceutical Industries Ltd (India), Actavis, Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Bayer AG (Germany), Teva Pharmaceutical Industries. Ltd. (Israel), Puma Biotechnology, Inc. (U.S.), and OncoGenex Pharmaceuticals Inc. (U.S.) to name a few.
In July 2017, U.S. FDA Approved the Puma Biotechnology’s Nerlynx (Neratinib) for the treatment of HER2-positive breast cancer in early stage
In July 2017, AstraZeneca received the approval from European Commission (EC) for Faslodex (fulvestrant) for the breast cancer treatment
1. EXECUTIVE SUMMARY
2. GLOBAL BREAST CANCER TREATMENT MARKET INTRODUCTION
2.1. Global Breast Cancer Treatment Market – Taxonomy
2.2. Global Breast Cancer Treatment Market –Definitions
2.2.1. Drug Class Type
2.2.2. Distribution Channel
3. GLOBAL BREAST CANCER TREATMENT MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Breast Cancer Treatment Market Dynamic Factors - Impact Analysis
3.6. Global Breast Cancer Treatment Market – Regulations
3.6.1. U.S.
3.6.2. Europe
3.7. Global Breast Cancer Treatment Market –Trends
4. GLOBAL BREAST CANCER TREATMENT MARKET ANALYSIS, 2012 – 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. GLOBAL BREAST CANCER TREATMENT MARKET, BY PRODUCT TYPE, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
5.1. Anthracyclines
5.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Antimetabolites
5.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Epothilones
5.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Taxanes
5.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Alkylating agents
5.5.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Hormonal therapy
5.6.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
5.7. Aromatase inhibitors
5.7.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.7.3. Market Opportunity Analysis
5.8. Selective Oestrogen-receptor modulators
5.8.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.8.3. Market Opportunity Analysis
5.9. Others
5.9.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.9.3. Market Opportunity Analysis
6. GLOBAL BREAST CANCER TREATMENT MARKET FORECAST, BY DISTRIBUTION CHANNEL TYPE, 2012 - 2016 AND FORECAST, 2017 – 2023
6.1. Hospital Pharmacies
6.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Retail Pharmacies
6.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Online Pharmacies
6.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
7. GLOBAL BREAST CANCER TREATMENT MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
7.1. North America
7.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Europe
7.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Asia-Pacific
7.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Latin America
7.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
7.5.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
7.6. Global Breast Cancer Treatment Market - Opportunity Analysis Index, By Drug Class Type, By Distribution Channel and Region, 2017 – 2023
8. NORTH AMERICA BREAST CANCER TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
8.1. Drug Class Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.1.1. Anthracyclines
8.1.2. Antimetabolites
8.1.3. Epothilones
8.1.4. Taxanes
8.1.5. Alkylating agents
8.1.6. Hormonal therapy
8.1.7. Aromatase inhibitors
8.1.8. Selective Oestrogen-receptor modulators
8.2. Distribution Channel Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
8.2.1. Hospital Pharmacies
8.2.2. Retail Pharmacies
8.2.3. Online Pharmacies
8.3. Country Analysis 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
8.3.1. U.S.
8.3.2. Canada
8.4. North America Breast Cancer Treatment Market - Opportunity Analysis Index, By Drug Class Type, By Distribution Channel and Country, 2017 – 2023
8.5. North America Breast Cancer Treatment Market Dynamics – Trends
9. EUROPE BREAST CANCER TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
9.1.1. Anthracyclines
9.1.2. Antimetabolites
9.1.3. Epothilones
9.1.4. Taxanes
9.1.5. Alkylating agents
9.1.6. Hormonal therapy
9.1.7. Aromatase inhibitors
9.1.8. Selective Oestrogen-receptor modulators
9.2. Distribution Channel Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.2.1. Hospital Pharmacies
9.2.2. Retail Pharmacies
9.2.3. Online Pharmacies
9.3. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.3.1. Germany
9.3.2. UK
9.3.3. France
9.3.4. Spain
9.3.5. Italy
9.3.6. Russia
9.3.7. Poland
9.3.8. Rest of Europe
9.4. Europe Breast Cancer Treatment Market - Opportunity Analysis Index, By Drug Class Type, By Distribution Channel and Country, 2017 – 2023
9.5. Europe Breast Cancer Treatment Market Dynamics – Trends
10. ASIA-PACIFIC BREAST CANCER TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
10.1.1. Anthracyclines
10.1.2. Antimetabolites
10.1.3. Epothilones
10.1.4. Taxanes
10.1.5. Alkylating agents
10.1.6. Hormonal therapy
10.1.7. Aromatase inhibitors
10.1.8. Selective Oestrogen-receptor modulators
10.2. Distribution Channel Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Hospital Pharmacies
10.2.2. Retail Pharmacies
10.2.3. Online Pharmacies
10.3. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.3.1. Japan
10.3.2. China
10.3.3. India
10.3.4. ASEAN
10.3.5. Australia & New Zealand
10.3.6. Rest of Asia-Pacific
10.4. Asia-Pacific Breast Cancer Treatment Market - Opportunity Analysis Index, By Drug Class Type, By Distribution Channel and Country, 2017 – 2023
10.5. Asia-Pacific Breast Cancer Treatment Market Dynamics – Trends
11. LATIN AMERICA BREAST CANCER TREATMENT MARKET ANALYSIS, 2012 - 2012 - 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
11.1.1. Anthracyclines
11.1.2. Antimetabolites
11.1.3. Epothilones
11.1.4. Taxanes
11.1.5. Alkylating agents
11.1.6. Hormonal therapy
11.1.7. Aromatase inhibitors
11.1.8. Selective Oestrogen-receptor modulators
11.2. Distribution Channel Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Hospital Pharmacies
11.2.2. Retail Pharmacies
11.2.3. Online Pharmacies
11.3. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.3.1. Brazil
11.3.2. Mexico
11.3.3. Argentina
11.3.4. Venezuela
11.3.5. Rest of Latin America
11.4. Latin America Breast Cancer Treatment Market - Opportunity Analysis Index, By Drug Class Type, By Distribution Channel and Country, 2017 – 2023
11.5. Latin America Breast Cancer Treatment Market Dynamics – Trends
12. MIDDLE EAST AND AFRICA BREAST CANCER TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
12.1.1. Anthracyclines
12.1.2. Antimetabolites
12.1.3. Epothilones
12.1.4. Taxanes
12.1.5. Alkylating agents
12.1.6. Hormonal therapy
12.1.7. Aromatase inhibitors
12.1.8. Selective Oestrogen-receptor modulators
12.2. Distribution Channel Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Hospital Pharmacies
12.2.2. Retail Pharmacies
12.2.3. Online Pharmacies
12.3. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.3.1. Gulf Cooperation Council (GCC) Countries
12.3.2. Israel
12.3.3. South Africa
12.3.4. Rest of MEA
12.4. MEA Breast Cancer Treatment Market - Opportunity Analysis Index, By Drug Class Type, By Distribution Channel and Country, 2017 – 2023
12.5. MEA Breast Cancer Treatment Market Dynamics – Trends
13. COMPETITION LANDSCAPE
13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
13.2.1. AstraZeneca (U.K.)
13.2.2. GlaxoSmithKline plc (U.K.)
13.2.3. Eli Lilly and Company (U.S.)
13.2.4. F. Hoffmann-La Roche Ltd (Switzerland)
13.2.5. Novartis AG (Switzerland)
13.2.6. Sanofi (France)
13.2.7. Pfizer, Inc (U.S.)
13.2.8. Sun Pharmaceutical Industries Ltd (India)
13.2.9. Actavis, Inc. (U.S.)
13.2.10. Bristol-Myers Squibb Company (U.S.)
13.2.11. Bayer AG (Germany)
13.2.12. Teva Pharmaceutical Industries. Ltd. (Israel)
13.2.13. Puma Biotechnology, Inc. (U.S.)
13.2.14. OncoGenex Pharmaceuticals Inc. (U.S.)
14. RESEARCH METHODOLOGY
15. KEY ASSUMPTIONS AND ACRONYMS
2. GLOBAL BREAST CANCER TREATMENT MARKET INTRODUCTION
2.1. Global Breast Cancer Treatment Market – Taxonomy
2.2. Global Breast Cancer Treatment Market –Definitions
2.2.1. Drug Class Type
2.2.2. Distribution Channel
3. GLOBAL BREAST CANCER TREATMENT MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Breast Cancer Treatment Market Dynamic Factors - Impact Analysis
3.6. Global Breast Cancer Treatment Market – Regulations
3.6.1. U.S.
3.6.2. Europe
3.7. Global Breast Cancer Treatment Market –Trends
4. GLOBAL BREAST CANCER TREATMENT MARKET ANALYSIS, 2012 – 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. GLOBAL BREAST CANCER TREATMENT MARKET, BY PRODUCT TYPE, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
5.1. Anthracyclines
5.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Antimetabolites
5.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Epothilones
5.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Taxanes
5.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Alkylating agents
5.5.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Hormonal therapy
5.6.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
5.7. Aromatase inhibitors
5.7.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.7.3. Market Opportunity Analysis
5.8. Selective Oestrogen-receptor modulators
5.8.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.8.3. Market Opportunity Analysis
5.9. Others
5.9.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.9.3. Market Opportunity Analysis
6. GLOBAL BREAST CANCER TREATMENT MARKET FORECAST, BY DISTRIBUTION CHANNEL TYPE, 2012 - 2016 AND FORECAST, 2017 – 2023
6.1. Hospital Pharmacies
6.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Retail Pharmacies
6.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Online Pharmacies
6.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
7. GLOBAL BREAST CANCER TREATMENT MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
7.1. North America
7.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Europe
7.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Asia-Pacific
7.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Latin America
7.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
7.5.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
7.6. Global Breast Cancer Treatment Market - Opportunity Analysis Index, By Drug Class Type, By Distribution Channel and Region, 2017 – 2023
8. NORTH AMERICA BREAST CANCER TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
8.1. Drug Class Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.1.1. Anthracyclines
8.1.2. Antimetabolites
8.1.3. Epothilones
8.1.4. Taxanes
8.1.5. Alkylating agents
8.1.6. Hormonal therapy
8.1.7. Aromatase inhibitors
8.1.8. Selective Oestrogen-receptor modulators
8.2. Distribution Channel Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
8.2.1. Hospital Pharmacies
8.2.2. Retail Pharmacies
8.2.3. Online Pharmacies
8.3. Country Analysis 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
8.3.1. U.S.
8.3.2. Canada
8.4. North America Breast Cancer Treatment Market - Opportunity Analysis Index, By Drug Class Type, By Distribution Channel and Country, 2017 – 2023
8.5. North America Breast Cancer Treatment Market Dynamics – Trends
9. EUROPE BREAST CANCER TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
9.1.1. Anthracyclines
9.1.2. Antimetabolites
9.1.3. Epothilones
9.1.4. Taxanes
9.1.5. Alkylating agents
9.1.6. Hormonal therapy
9.1.7. Aromatase inhibitors
9.1.8. Selective Oestrogen-receptor modulators
9.2. Distribution Channel Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.2.1. Hospital Pharmacies
9.2.2. Retail Pharmacies
9.2.3. Online Pharmacies
9.3. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.3.1. Germany
9.3.2. UK
9.3.3. France
9.3.4. Spain
9.3.5. Italy
9.3.6. Russia
9.3.7. Poland
9.3.8. Rest of Europe
9.4. Europe Breast Cancer Treatment Market - Opportunity Analysis Index, By Drug Class Type, By Distribution Channel and Country, 2017 – 2023
9.5. Europe Breast Cancer Treatment Market Dynamics – Trends
10. ASIA-PACIFIC BREAST CANCER TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
10.1.1. Anthracyclines
10.1.2. Antimetabolites
10.1.3. Epothilones
10.1.4. Taxanes
10.1.5. Alkylating agents
10.1.6. Hormonal therapy
10.1.7. Aromatase inhibitors
10.1.8. Selective Oestrogen-receptor modulators
10.2. Distribution Channel Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Hospital Pharmacies
10.2.2. Retail Pharmacies
10.2.3. Online Pharmacies
10.3. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.3.1. Japan
10.3.2. China
10.3.3. India
10.3.4. ASEAN
10.3.5. Australia & New Zealand
10.3.6. Rest of Asia-Pacific
10.4. Asia-Pacific Breast Cancer Treatment Market - Opportunity Analysis Index, By Drug Class Type, By Distribution Channel and Country, 2017 – 2023
10.5. Asia-Pacific Breast Cancer Treatment Market Dynamics – Trends
11. LATIN AMERICA BREAST CANCER TREATMENT MARKET ANALYSIS, 2012 - 2012 - 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
11.1.1. Anthracyclines
11.1.2. Antimetabolites
11.1.3. Epothilones
11.1.4. Taxanes
11.1.5. Alkylating agents
11.1.6. Hormonal therapy
11.1.7. Aromatase inhibitors
11.1.8. Selective Oestrogen-receptor modulators
11.2. Distribution Channel Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Hospital Pharmacies
11.2.2. Retail Pharmacies
11.2.3. Online Pharmacies
11.3. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.3.1. Brazil
11.3.2. Mexico
11.3.3. Argentina
11.3.4. Venezuela
11.3.5. Rest of Latin America
11.4. Latin America Breast Cancer Treatment Market - Opportunity Analysis Index, By Drug Class Type, By Distribution Channel and Country, 2017 – 2023
11.5. Latin America Breast Cancer Treatment Market Dynamics – Trends
12. MIDDLE EAST AND AFRICA BREAST CANCER TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
12.1.1. Anthracyclines
12.1.2. Antimetabolites
12.1.3. Epothilones
12.1.4. Taxanes
12.1.5. Alkylating agents
12.1.6. Hormonal therapy
12.1.7. Aromatase inhibitors
12.1.8. Selective Oestrogen-receptor modulators
12.2. Distribution Channel Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Hospital Pharmacies
12.2.2. Retail Pharmacies
12.2.3. Online Pharmacies
12.3. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.3.1. Gulf Cooperation Council (GCC) Countries
12.3.2. Israel
12.3.3. South Africa
12.3.4. Rest of MEA
12.4. MEA Breast Cancer Treatment Market - Opportunity Analysis Index, By Drug Class Type, By Distribution Channel and Country, 2017 – 2023
12.5. MEA Breast Cancer Treatment Market Dynamics – Trends
13. COMPETITION LANDSCAPE
13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
13.2.1. AstraZeneca (U.K.)
13.2.2. GlaxoSmithKline plc (U.K.)
13.2.3. Eli Lilly and Company (U.S.)
13.2.4. F. Hoffmann-La Roche Ltd (Switzerland)
13.2.5. Novartis AG (Switzerland)
13.2.6. Sanofi (France)
13.2.7. Pfizer, Inc (U.S.)
13.2.8. Sun Pharmaceutical Industries Ltd (India)
13.2.9. Actavis, Inc. (U.S.)
13.2.10. Bristol-Myers Squibb Company (U.S.)
13.2.11. Bayer AG (Germany)
13.2.12. Teva Pharmaceutical Industries. Ltd. (Israel)
13.2.13. Puma Biotechnology, Inc. (U.S.)
13.2.14. OncoGenex Pharmaceuticals Inc. (U.S.)
14. RESEARCH METHODOLOGY
15. KEY ASSUMPTIONS AND ACRONYMS
